skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

開発中の医薬品をFDA承認確率で示すデータベース

Biomedtracker | Pharma intelligence

Biomedtracker(バイオメドトラッカー)では、アメリカの医薬品開発プロセスの動きを2003年以降独自に分析しています。弊社アナリストチームが下記に挙げる代表的なイベントと、それらによるインパクトを発生と同時に分析&評価し、アメリカ食品医薬品局(FDA)の承認確率(LOA: Likelihood of Approval)で提示します。そうすることで、医薬品の開発動向をいち早く正確に把握できるデータベースがBiomedtrackerです。

医薬品開発に大きな影響を与える代表的なイベントやカタリストの例:

  • 臨床試験の開始や結果報告
  • 学会やカンファレンスにおける発表
  • ライセンス、M&A、提携に関する活動
  • 企業発表(プレスリリース、収支報告、投資家向け情報)
  • 薬事行政の動向、など

Biomedtrackerをご利用いただくことのメリット:

公平性&即時性
第三者的立場からバイアスのないコメントを付与し、情報をほぼ即日更新します。

イベントの種類が豊富&検索可能
会社情報、特許、開発品の進捗、承認申請、臨床試験結果報告など275種類。過去のイベントは時系列で確認できます。

学会の情報収集など関連情報へのアクセス
アナリストが参加した学会のレポートを発行します(例: JP Morgan, ASCO, ASH, AAN, ATSなど)。お客様が参加することができなかった海外の学会に関する情報を収集できます。また、アメリカ食品医薬品局(FDA)諮問委員会での評価・投票結果やKOL(Key Opinion Leader)インタビュー、弊社が発行する様々なレポートにもアクセスできます。

Datamonitor Healthcareとの併用が効果的です
開発中医薬品をリアルタイムで追跡するBiomedtrackerは、医薬品の市場調査レポートライブラリーである姉妹サービスDatamonitor Healthcareとの併用が効果的です。ぜひ合わせてご検討ください。

 

【お知らせ】無料オンラインサービス説明会&トレーニングを開催します!
『開発品をFDA承認確率でみるBiomedtrackerについて』2018年10月10日(水)16時~17時、お申し込みはこちらから

このサービスの特徴

無料の最新記事&レポート

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    Biomedtracker Q3 2019 Outlook Report Extract

    29 Jul 2019

    In this report, we cover catalysts from 27 drugs, devices and diagnostics expected to occur in Q3 2019. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. These data points were provided using a combination of Pharmapremia, Informa’s drug development benchmarking product utilizing Biomedtracker’s LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker.   

    Topic drug-development-landscape drug-review research strategy

  • Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Biomedtracker: 開発中医...

    2019 Q3 Outlook Webinar

    By Hardik Patel 15 Jul 2019

    Informa Pharma Intelligence presents an essential, free session during which industry analysts present their data-driven views about what to expect during the third quarter of 2019. 

    Topic immuno-oncology infectious-diseases

  • Meddevicetracker: 医療機器の市場調査分析・データベース, Biomedtracker: 開発中医薬品を...

    When Part of the Picture Isn't Enough

    05 Jul 2019

    Staying on top of what’s going in the competitive Medtech market and getting a complete view of the competitive landscape and current market trends is critical to your business. Often, this essential information is fragmented and difficult to find, and gathering and synthesizing it is tedious and time consuming. Now, Biomedtracker puts this critical information at your fingertips, saving you time and effort. The new “Associated Products” section on relevant Biomedtracker Drug Profile pages shows you the full competitive landscape – including drugs, devices, and diagnostics – with a single search.

    Topic business-strategies medtech

  • Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Biomedtracker: 開発中医...

    Q1 Outlook Webinar: Key Catalysts and their Impact on Pharma Markets

    02 Jul 2019

    Find out which market-moving events and catalysts to watch for during the Q1 Outlook Webinar - Key catalysts and their impact on pharma markets.

    Topic drug-approval drug-development-landscape drug-review

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    Biomedtracker: Catalyst Roundup 2018 Q4

    02 Jul 2019

    A Review of Select Catalysts from Last Quarter’s Outlook Report.

    Topic clinical-trials drug-approval drug-review drug-development-landscape

  • Meddevicetracker: 医療機器の市場調査分析・データベース, Biomedtracker: 開発中医薬品を...

    Q2 2019 Outlook Report

    03 May 2019

    In this report, we cover catalysts from 25 drugs, devices and diagnostics expected to occur in Q2 2019. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

    Topic drug-approval drug-development-landscape drug-review

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor Healthcare: 医療...

    December 2018 National Influenza Week

    10 Apr 2019

    3 – 9 December is National Influenza Vaccination Week, a national awareness week focused on highlighting the importance of influenza vaccination. In this free KOL Insight Interview excerpt from Datamonitor Healthcare, read what key opinion leaders from the UK and US in Infectious Diseases have to say about current efforts to combat influenza with seasonal influenza vaccines:

    Topic influenza-virus infectious-diseases

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    Biomedtracker 2018 Early Outlook Report

    10 Apr 2019

    What's on the horizon for pharma in 2018? Find out with Biomedtracker's Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.

    Topic drug-development-landscape

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Meddevicetracker: 医療機器の市場調...

    Biomedtracker: Early 2019 Outlook Report Extract

    10 Apr 2019

    In this report, we cover catalysts from 23 drugs, devices and diagnostics expected to occur in early 2019.

    Topic drug-approval drug-review medtech

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    Q4 Outlook Webinar - Key Catalysts and their Impact on Pharma Markets

    19 Nov 2018

    Understand important upcoming milestones that will impact the likelihood of drug approval or future sales potential for key therapies during a free webinar from Informa Pharma Intelligence, "Q4 Outlook Webinar - Key Catalysts and their Impact on Pharma Markets".

    Topic drug-development-landscape

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    Biomedtracker Q4 2018 Outlook Report

    19 Oct 2018

    Find out what’s in store for the remainder of 2018 with your copy of the Biomedtracker Q4 2018 Outlook Report Extract. This essential analysis of expected Q4 catalysts for 27 drugs is now available to you – for free. Drawn from the full report of the same name, this vital resource explores the likelihood of phase/PDUFA review success and overall Likelihood of Approval (LOA) based on a drug’s phase, drug class, and disease group.

    Topic drug-development-landscape

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    Pharma Partnering Trends Revealed Whitepaper

    12 Oct 2018

    Make the most of BIO-Europe 2018 with essential partnering information from Informa Pharma Intelligence. Our insightful whitepaper, Pharma Partnering Trends Revealed: 2018 Edition, contains critical information on the landscape for biotech partnerships, and is now available for you to download – free.

  • Biomedtracker

    Biomedtracker Q3 2018 Outlook Infographic

    22 Aug 2018

    For a look at the outcomes for predicted Q2 2018 catalysts, we invite you to download a free copy of the data-rich Catalyst Roundup infographic from Biomedtracker. This informative graphic takes a look at the outcomes for two major catalysts featured in Biomedtracker’s insightful Q2 2018 Outlook Report.

    Topic drug-development-landscape

  • Biomedtracker

    Biomedtracker Q3 2018 Outlook Report Extract

    15 Aug 2018

    Download an extract of the data-rich resource: Biomedtracker’s Q3 2018 Outlook Report. This latest installment in Biomedtracker’s ongoing quarterly reports contains expected drug catalyst predictions, important clinical and regulatory milestones, and Large Impact catalysts for the upcoming quarter. 

    Topic drug-development-landscape

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース, Biomedtracker: 開発中医薬品をFDA承認確率...

    ASCO Essentials Webinar 2018 Recording

    29 May 2018

    Just in time for your 2018 ASCO Annual Meeting planning, join analysts from Datamonitor Healthcare, Biomedtracker, Citeline, Scrip, and Pink Sheet for their expert opinions on what you need to know to get the most from the meeting. Let our experts present their top picks from the thousands of abstracts being presented at ASCO.

    Topic clinical-trials

医薬品産業専門のジャーナリスト&アナリスト

Management

Patricia Reilly

Management, VP, Intelligence Alliances and Product Unification
Patricia Reilly

Patricia specializes in

  • CNS
  • Immunology and Inflammation
  • Oncology

+27 year(s) experience

Management

Gail Parziale

Management, ​Head of Intelligence Editorial Operations
Gail Parziale

Gail specializes in

  • Commercial Strategy
  • Clinical Trials

+22 year(s) experience

Analyst

Rachel Meighan-Mantha

Analyst, Principal Analyst
Rachel Meighan-Mantha

Rachel specializes in

  • Oncology
  • Clinical Trials

+22 year(s) experience

製品説明を兼ねた無料デモ&お問い合わせ

専任スタッフによる詳しい説明を兼ねた無料デモンストレーションを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。